1,500
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis

, , , , , , & show all
Pages 1215-1218 | Received 14 Jun 2015, Accepted 25 Jul 2015, Published online: 05 Oct 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Achille Pich, Eloise Beggiato, Laura Godio, Ludovica Riera, Paola Francia di Celle, Giuseppe Lanzarone & Giulia Benevolo. (2021) Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms. Expert Review of Hematology 14:9, pages 841-850.
Read now

Articles from other publishers (3)

Rachel B. Salit, Bart L. Scott, Emily A. Stevens, Kelsey K. Baker, Ted A. Gooley & H. Joachim Deeg. (2019) Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transplantation 55:1, pages 70-76.
Crossref
Rafael Kramann & Rebekka K. Schneider. (2018) The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood 131:19, pages 2111-2119.
Crossref
G Caocci, M Greco, G Delogu, C Secchi, A Perra, S Ghiani, F Orru, A Vacca, F Galimi & G La Nasa. (2016) Ruxolitinib therapy and telomere length in myelofibrosis. Blood Cancer Journal 6:10, pages e479-e479.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.